US EditionWeight-loss company Noom pivots to smaller doses of compounded Wegovy
- In 2025, Noom, an online weight-loss service, started providing personalized treatments featuring low-dose compounded formulations of Novo Nordisk's Wegovy in the United States.
- This shift follows increasing FDA scrutiny and tightening regulations on mass production of compounded semaglutide drugs, which include Wegovy's active ingredient.
- Noom's new personalized program offers compounded semaglutide at $149 for the first month, compared to $349 per 2.5 mg vial of branded Wegovy or Zepbound.
- According to Noom's chief medical officer, smaller doses address side effects and help maintain weight loss, while complying with FDA regulations and responding to high drug costs.
- The move reflects telehealth companies' need to adapt to regulatory changes and patient demand for affordable, effective weight-loss treatments amid ongoing FDA reviews.
11 Articles
11 Articles
Weight-loss company Noom pivots to smaller doses of compounded Wegovy
Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S. drugs regulator clamps down on mass production of copies of the in-demand medicine.
Weight-Loss Drug Lawsuits: Vision Loss Claims Surge – Archyde: Latest World News, Economy, Entertainment, Health, Technology & Sports Updates
Archyde: Latest World News, Economy, Entertainment, Health, Technology & Sports Updates Ozempic and Vision Loss: Unveiling the Emerging Risks and lawsuits The rising popularity of weight-loss drugs like Ozempic has been accompanied by growing concerns about potential side effects, including a disturbing number of reports linking thes medications to vision loss. More than a dozen lawsuits have been filed by individuals claiming that their eyesigh…
Coverage Details
Bias Distribution
- 75% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
